PCN161 Disease Burden of Multiple Myeloma (MM) in France: A Descriptive Study Based on a French Medico-Administrative Database

Abstract

Multiple Myeloma (MM) is a malignant hemopathy. The disease is identified by a severe proliferation of plasma cell in bone marrow for which there is still a lack of economic evidence. The objective of this study is to estimate the MM burden disease in the French setting. The EGB (Echantillon Généraliste de Bénéficiaires) database, a 1/97th random sample of the French healthcare insurance database linked with the hospital discharge database (PMSI) was used for this study. Retrospective data between 2014 and 2017 were considered to identify incident cases of MM. The index admission was the first admission with principal diagnosis for MM (ICD-10: C90) and patients had to be clear of MM admission in the 5 previous years. Healthcare costs were analyzed from the national health insurance perspective. The study period included the first-year period following the initial diagnosis, and the second-year period following the initial diagnosis. Additional costs attributable to the disease were estimated by comparing the incident CLL cohort to a matched cohort, on age and gender, with a 1:5 ratio. The study identified 150 incident cases with a mean age of 73 years (SD: 11), 47% were women, 16% had severe comorbidities (Charlson index ≥3) and 33 deaths (22%) were observed during the study period. Monthly additional cost during the first-year period was estimate at €5,259. Main drivers of costs were admissions (€2,478) and pharmaceuticals (€2,366) and 28 patients (19%) had transplantation (autograft or allograft). Monthly additional cost for the second year of follow-up was estimated at €1,407. This study confirms the significant economic burden of CLL disease in France and provide up-to-date economic data that could support decision making.